{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:36:06Z","timestamp":1777383366693,"version":"3.51.4"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1735,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Chronic hepatitis B virus (HBV) infection in children presents a therapeutic challenge for the practitioner. Decisions regarding selection of patients who may bene\ufb01t from treatment, appropriate timing of treatment, and the choice of antiviral therapy are complex and are compounded by the limited number of drugs that have been studied in children. An expert panel of nationally recognized pediatric liver specialists was convened by the Hepatitis B Foundation on August 11, 2009, to consider clinical practice relative to the therapeutic options available for children. A detailed account of these discussions is provided, and the opinions expressed are based on consensus of the experts, as well as on published evidence when available. The panel concludes that, at this time, there is no established bene\ufb01t of treatment of children in the immune tolerant phase, and there is a very high risk of devel-opment of drug resistance. In addition, there is no indication for treatment of children in the inactive carrier state. For children in the immune active or reactivation phases, liver histology can help guide treatment decisions, and family history of liver disease, especially hepatocellular carcinoma, may argue for early treatment in some cases. Outside of clinical trials, interferon is the agent of choice in most cases. Nucleos(t)ide analogues are secondary therapies, and children who receive these agents require careful monitoring for development of resistance. There are a few situations when treatment is indicated regardless of HBV DNA or alanine aminotransferase levels. There is still much to be elucidated about the appropriate use of HBV therapy in children. Until more clinical data and therapeutic options are avail-able, a conservative approach is warranted. (HEPATOLOGY 2010;52:2192-2205)<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.23934","type":"journal-article","created":{"date-parts":[[2010,8,29]],"date-time":"2010-08-29T19:13:06Z","timestamp":1283109186000},"page":"2192-2205","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":123,"title":["Treatment of Children With Chronic Hepatitis B Virus Infection in the United States"],"prefix":"10.1097","volume":"52","author":[{"given":"Maureen M.","family":"Jonas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan M.","family":"Block","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara A.","family":"Haber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saul J.","family":"Karpen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. Thomas","family":"London","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen F.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Narkewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen B.","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-35-20251124","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cgh.2008.08.021","article-title":"A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update","volume":"6","author":"Keeffe","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R2-35-20251124","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12072-008-9080-3","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update","volume":"2","author":"Liaw","year":"2008","journal-title":"Hepatol Int"},{"key":"R3-35-20251124","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.jhep.2008.10.001","article-title":"EASL Clinical Practice Guidelines: management of chronic hepatitis B.","volume":"50","year":"2009","journal-title":"J Hepatol"},{"key":"R5-35-20251124","doi-asserted-by":"crossref","first-page":"e1007","DOI":"10.1542\/peds.2009-0567","article-title":"Recommendations for screening, monitoring, and referral of pediatric chronic hepatitis B","volume":"124","author":"Haber","year":"2009","journal-title":"Pediatrics"},{"key":"R6-35-20251124","first-page":"1","article-title":"A Comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: Immunization of infants, children, and adolescents","volume":"54","author":"Mast","year":"2005","journal-title":"MMWR"},{"key":"R7-35-20251124","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1086\/514610","article-title":"Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors","volume":"27","author":"Ngui","year":"1998","journal-title":"Clin Infect Dis"},{"key":"R8-35-20251124","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(83)90624-4","article-title":"Prevention of perinatally transmitted hepatitis B virus infections with hepatitis B virus infections with hepatitis B immune globulin and hepatitis B vaccine","volume":"2","author":"Beasley","year":"1983","journal-title":"Lancet"},{"key":"R9-35-20251124","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state","volume":"151","author":"McMahon","year":"1985","journal-title":"J Infect Dis"},{"key":"R10-35-20251124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.1890220102","article-title":"Age- and sex-related study of hepatitis B virus chronic carrier state in infants from an endemic area (Senegal)","volume":"22","author":"Coursaget","year":"1987","journal-title":"J Med Virol"},{"key":"R11-35-20251124","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1002\/hep.21627","article-title":"Management of hepatitis B: summary of a clinical research workshop","volume":"45","author":"Hoofnagle","year":"2007","journal-title":"HEPATOLOGY"},{"key":"R12-35-20251124","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1002\/hep.22898","article-title":"The natural history of chronic hepatitis B virus infection","volume":"49","author":"McMahon,","year":"2009","journal-title":"HEPATOLOGY"},{"key":"R13-35-20251124","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/jmv.1890180402","article-title":"Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan","volume":"18","author":"Hsu","year":"1986","journal-title":"J Med Virol"},{"key":"R14-35-20251124","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0016-5085(90)90972-4","article-title":"Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood","volume":"99","author":"Bortolotti","year":"1990","journal-title":"Gastroenterology"},{"key":"R15-35-20251124","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0168-8278(98)80002-0","article-title":"Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period","volume":"29","author":"Bortolotti","year":"1998","journal-title":"J Hepatol"},{"key":"R16-35-20251124","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1053\/j.gastro.2007.08.010","article-title":"Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F","volume":"133","author":"Livingston","year":"2007","journal-title":"Gastroenterology"},{"key":"R17-35-20251124","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"R18-35-20251124","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cld.2007.08.005","article-title":"Long-term outcomes in hepatitis B: The REVEAL-HBV Study","volume":"11","author":"Chen","year":"2007","journal-title":"Clin Liver Dis"},{"key":"R19-35-20251124","doi-asserted-by":"crossref","first-page":"58","DOI":"10.7326\/0003-4819-147-1-200707030-00010","article-title":"The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points","volume":"147","author":"Lai","year":"2007","journal-title":"Ann Intern Med"},{"key":"R20-35-20251124","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1111\/j.1572-0241.2007.01751.x","article-title":"Prevalence of fibrosis and cirrhosis in chronic hepatitis B: implications for treatment and management","volume":"103","author":"Fung","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"R21-35-20251124","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.20933","article-title":"AASLD Practice Guideline: Management of hepatocellular carcinoma","volume":"42","author":"Bruix","year":"2005","journal-title":"HEPATOLOGY"},{"key":"R22-35-20251124","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/hep.23464","article-title":"Clearance of hepatitis B surface antigen and risk of hepatocellular carcinoma in a cohort chronically infected with hepatitis B virus","volume":"51","author":"Simonetti","year":"2010","journal-title":"HEPATOLOGY"},{"key":"R23-35-20251124","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jpeds.2003.11.022","article-title":"The development of hepatocellular carcinoma among prospectively followed children with chronic hepatitis B virus infection","volume":"144","author":"Wen","year":"2004","journal-title":"J Pediatr"},{"key":"R24-35-20251124","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1023\/A:1026609231094","article-title":"Progressive liver functional impairment is associated with an increase in AST\/ALT ratio","volume":"44","author":"Giannini","year":"1999","journal-title":"Dig Dis Sci"},{"key":"R25-35-20251124","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1572-0241.1998.044_c.x","article-title":"AST\/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection","volume":"93","author":"Sheth","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"R26-35-20251124","first-page":"386","article-title":"Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis Gastroenterol H","volume":"15","author":"Park","year":"2000","journal-title":"epatol"},{"key":"R27-35-20251124","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1478-3231.2009.02192.x","article-title":"Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients","volume":"30","author":"Kim","year":"2010","journal-title":"Liver Int"},{"key":"R28-35-20251124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7326\/0003-4819-137-1-200207020-00006","article-title":"Updated definitions of healthy ranges for serum alanine aminotransferase levels","volume":"137","author":"Prati","year":"2002","journal-title":"Ann Intern Med"},{"key":"R29-35-20251124","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jpeds.2005.09.020","article-title":"Combined lamivudine\/interferon-alpha treatment in \u201cimmunotolerant\u201d children perinatally infected with hepatitis B: a pilot study","volume":"148","author":"D'Antiga","year":"2006","journal-title":"J Pediatr"},{"key":"R30-35-20251124","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.inf.0000059443.49414.8b","article-title":"Therapeutic vaccination in the immunotolerant phase of children with chronic hepatitis B infection","volume":"22","author":"Dikici","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"R31-35-20251124","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1442-200X.2007.02419.x","article-title":"Efficacy of vitamin E in children with immunotolerant-phase chronic hepatitis B infection","volume":"49","author":"Dikici","year":"2007","journal-title":"Pediatr Int"},{"key":"R32-35-20251124","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos (t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"R33-35-20251124","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1053\/j.gastro.2009.12.052","article-title":"SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease","volume":"138","author":"Schwimmer","year":"2010","journal-title":"Gastroenterology"},{"key":"R34-35-20251124","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S0016-5085(98)70318-X","article-title":"Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial","volume":"114","author":"Sokal","year":"1998","journal-title":"Gastroenterology"},{"key":"R35-35-20251124","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa012452","article-title":"Clinical trial of lamivudine in children with chronic hepatitis B","volume":"346","author":"Jonas","year":"2002","journal-title":"N Engl J Med"},{"key":"R36-35-20251124","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1002\/hep.22250","article-title":"Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (aged 2 to <18 years) with chronic hepatitis B","volume":"47","author":"Jonas","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R37-35-20251124","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"R38-35-20251124","first-page":"995","article-title":"Spontaneous clearance of high-titer serum HBV DNA and risk of hepatocellular carcinoma in a Chinese population","volume":"14","author":"Harris","year":"2003","journal-title":"Cancer Causes Control"},{"key":"R39-35-20251124","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"R40-35-20251124","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/MPG.0b013e318197196e","article-title":"Management of chronic hepatitis B in children","volume":"48","author":"Shah","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R41-35-20251124","first-page":"768","article-title":"Serologic and clinical outcomes in 1536 Alaska Natives chronically infected with hepatitis B virus.","volume":"759-","author":"McMahon","year":"2001","journal-title":"Ann Intern Med"},{"key":"R42-35-20251124","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3748\/wjg.v12.i11.1713","article-title":"Inter-observer variability in histopathological assessment of liver biopsies taken in a pediatric open label therapeutic program for chronic HBV infection treatment","volume":"12","author":"Woynarowski","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R43-35-20251124","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/01.inf.0000126412.93562.f5","article-title":"Predictors of virologic response to lamivudine treatment in children with chronic hepatitis B","volume":"23","author":"Hom","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"R44-35-20251124","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1055\/s-2007-984696","article-title":"Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy","volume":"27","author":"Terrault","year":"2007","journal-title":"Semin Liver Dis"},{"key":"R45-35-20251124","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-2893.2007.00902.x","article-title":"Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis","volume":"15","author":"Katz","year":"2008","journal-title":"J Viral Hepat"},{"key":"R46-35-20251124","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1440-1746.2002.02737.x","article-title":"Hepatitis B viral genotypes: clinical relevance and molecular characteristics","volume":"17","author":"Kao","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"R47-35-20251124","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1099\/0022-1317-83-8-2059","article-title":"Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America","volume":"83","author":"Arauz-Ruiz","year":"2002","journal-title":"J Gen Virol"},{"key":"R48-35-20251124","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s12072-008-9112-z","article-title":"The influence of hepatitis B genotype and subgenotype on the natural history of chronic hepatitis B","volume":"3","author":"McMahon,","year":"2009","journal-title":"Hepatol Int"},{"key":"R49-35-20251124","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1136\/gut.2003.033324","article-title":"Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma","volume":"53","author":"Chan","year":"2004","journal-title":"Gut"},{"key":"R50-35-20251124","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1002\/hep.20240","article-title":"HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects","volume":"39","author":"Yuen","year":"2004","journal-title":"HEPATOLOGY"},{"key":"R51-35-20251124","first-page":"1425","article-title":"HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C","volume":"36","author":"Wai","year":"2002","journal-title":"HEPATOLOGY"},{"key":"R52-35-20251124","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1136\/gut.2004.060327","article-title":"Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D","volume":"54","author":"Erhardt","year":"2005","journal-title":"Gut"},{"key":"R53-35-20251124","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.cld.2005.10.005","article-title":"Hepatitis B and C in children: current treatment and future strategies","volume":"10","author":"Elisofon","year":"2006","journal-title":"Clin Liver Dis"},{"key":"R54-35-20251124","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0168-8278(05)80624-5","article-title":"The value of quantitative measurement of HBeAg and HBsAg before interferon-alpha treatment of chronic hepatitis B in children","volume":"21","author":"Burczynska","year":"1994","journal-title":"J Hepatol"},{"key":"R55-35-20251124","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-3476(95)70181-8","article-title":"Clearance of chronic hepatitis B virus infection in young children after alpha interferon treatment","volume":"127","author":"Narkewicz","year":"1995","journal-title":"J Pediatr"},{"key":"R56-35-20251124","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.jpeds.2004.05.046","article-title":"Interferon treatment for chronic hepatitis B: enhanced response in children 5 years old or younger","volume":"145","author":"Kobak","year":"2004","journal-title":"J Pediatr"},{"key":"R57-35-20251124","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/00365540802154769","article-title":"Treatment of chronic hepatitis B infection: an update of Swedish recommendations","volume":"40","author":"Lindh","year":"2008","journal-title":"Scand J Infect Dis"},{"key":"R58-35-20251124","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/hep.21020","article-title":"Long-term lamivudine therapy for children with HBeAg-positive chronic hepatitis B","volume":"43","author":"Sokal","year":"2006","journal-title":"HEPATOLOGY"},{"key":"R59-35-20251124","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1365-2893.2007.00891.x","article-title":"and members of the International Pediatric Lamivudine Investigator Group. Long-term lamuvidine treatment of children with chronic hepatitis B: durability of therapeutic responses and safety","volume":"15","author":"Jonas","year":"2008","journal-title":"J Viral Hepat"},{"key":"R61-35-20251124","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12072-008-9048-3","article-title":"Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure","volume":"2","author":"Locarnini","year":"2008","journal-title":"Hepatol Int"},{"key":"R63-35-20251124","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/hep.22414","article-title":"Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B","volume":"48","author":"Marcellin","year":"2008","journal-title":"HEPATOLOGY"},{"key":"R64-35-20251124","first-page":"25","article-title":"Viral hepatitis and HIV in Africa","volume":"9","author":"Modi","year":"2007","journal-title":"AIDS Rev"},{"key":"R65-35-20251124","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1016\/S0140-6736(02)11913-1","article-title":"HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)","volume":"360","author":"Thio","year":"2002","journal-title":"Lancet"},{"key":"R66-35-20251124","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/hep.510300525","article-title":"Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients","volume":"30","author":"Benhamou","year":"1999","journal-title":"HEPATOLOGY"},{"key":"R67-35-20251124","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/01.aids.0000163948.62176.e7","article-title":"Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel","volume":"19","author":"Soriano","year":"2005","journal-title":"AIDS"},{"key":"R68-35-20251124","first-page":"1","article-title":"Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics","volume":"58","author":"Mofenson","year":"2009","journal-title":"MMWR Recomm Rep"},{"key":"R69-35-20251124","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2009.01.004","article-title":"Hepatitis D: thirty years after","volume":"50","author":"Rizzetto","year":"2009","journal-title":"J Hepatol"},{"key":"R70-35-20251124","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1053\/j.gastro.2009.01.052","article-title":"A 28-year study of the course of hepatitis Delta infection: a risk factor for cirrhosis and hepatocellular carcinoma","volume":"136","author":"Romeo","year":"2009","journal-title":"Gastroenterology"},{"key":"R71-35-20251124","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1478-3231.2008.01933.x","article-title":"Hepatitis B and pregnancy: an underestimated issue","volume":"29","author":"Jonas","year":"2009","journal-title":"Liver Int"},{"key":"R72-35-20251124","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jpeds.2007.12.020","article-title":"Decreased bone mineral density with off-label use of tenofovir in children and adolescents infected with human immunodeficiency virus","volume":"152","author":"Purdy","year":"2008","journal-title":"J Pediatr"},{"key":"R73-35-20251124","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.jhep.2008.01.011","article-title":"reflections on the current approach to antiviral therapy","volume":"48","author":"Zoulim","year":"2008","journal-title":"J Hepatol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23934","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201012000-00035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T19:00:58Z","timestamp":1764010858000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201012000-00035"}},"subtitle":["Patient Selection and Therapeutic Options"],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23934","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}